Armata Pharmaceuticals, Inc. (ARMP) said on Thursday that it will delay reporting its fourth-quarter and full-year 2025 results as it needs more time to complete financial reporting, and expects to file its annual report by March 31, 2026.
The company also provided business updates, highlighting that the U.S. Food and Drug Administration has granted its lead candidate AP-SA02 Qualified Infectious Disease Product status for treating serious Staphylococcus aureus infections, making it eligible for development incentives, including extended market exclusivity.
Armata said it plans to advance AP-SA02 into a Phase 3 trial in the second half of 2026.
The company also noted positive Phase 2a results for AP-SA02, with the therapy showing higher cure rates and strong response in patients with complicated Staphylococcus aureus infections when combined with standard antibiotics.
In addition, Armata said it has commissioned its cGMP manufacturing facility in Los Angeles to support future clinical and commercial production.
Armata shares closed at $8.54, down 11.13% on Wednesday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.